Indications
Treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (HIV 1) without known mutations associated with resistance to the non nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine and with a viral load ? 100,000 HIV 1 RNA copies/mL.
Composition
- Active substance
- emtricitabine, rilpivirine hydrochloride, tenofovir alafenamide
- International name (INN)
- emtricitabine;rilpivirine;tenofovir alafenamide
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Odefsey
- Active substance
- emtricitabine, rilpivirine hydrochloride, tenofovir alafenamide
- ATC code
- J05AR19